drugset / Trial / NCT00441597

Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?

NCT00441597 ↗

Phase 4 Completed 30 enrolled Radboud University Medical Center Pfizer · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

To study the impact of 3 day exposure to atorvastatin 80mg on Annexin A5 targeting after ischemic exercise in the non-dominant forearm.

Timeline

Start
2007-02
Primary completion
2009-02
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 80 mg —

Indications